Axiom International Investors LLC DE decreased its position in Immunomedics, Inc. (NASDAQ:IMMU) by 38.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 82,480 shares of the biopharmaceutical company’s stock after selling 51,370 shares during the period. Axiom International Investors LLC DE’s holdings in Immunomedics were worth $1,718,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of IMMU. First Allied Advisory Services Inc. bought a new position in Immunomedics during the second quarter worth about $205,000. Gideon Capital Advisors Inc. bought a new position in Immunomedics during the third quarter worth about $229,000. Jasper Ridge Partners L.P. bought a new position in Immunomedics during the second quarter worth about $259,000. Parametrica Management Ltd bought a new position in Immunomedics during the third quarter worth about $281,000. Finally, Bradley Foster & Sargent Inc. CT bought a new position in Immunomedics during the third quarter worth about $297,000. Hedge funds and other institutional investors own 75.96% of the company’s stock.
A number of equities analysts have issued reports on IMMU shares. BidaskClub cut Immunomedics from a “buy” rating to a “hold” rating in a report on Saturday, August 4th. B. Riley raised their target price on Immunomedics from $53.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, August 24th. Zacks Investment Research upgraded Immunomedics from a “sell” rating to a “hold” rating in a report on Wednesday, August 29th. TheStreet cut Immunomedics from a “c-” rating to a “d+” rating in a report on Tuesday, September 11th. Finally, Goldman Sachs Group started coverage on Immunomedics in a report on Monday, September 17th. They set a “buy” rating and a $36.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Immunomedics presently has a consensus rating of “Buy” and a consensus target price of $38.43.
Immunomedics (NASDAQ:IMMU) last released its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.06). Immunomedics had a negative return on equity of 85.57% and a negative net margin of 12,701.21%. During the same period last year, the business posted ($0.97) EPS. As a group, equities analysts predict that Immunomedics, Inc. will post -1.2 earnings per share for the current year.
Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.
Featured Article: Do stock splits help investors?
Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics, Inc. (NASDAQ:IMMU).
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.